AesRx
Newton, Massachusetts, United States
About AesRx
AesRx (À½s-r-ex) is a biopharmaceutical company dedicated to the development of two novel drugs, each of which targets an orphan disease. AesRx's lead program, Aes-103, is a potential breakthrough in the treatment of sickle cell disease. Sickle cell disease is a recessive disorder of the hemoglobin which can cause red blood cells to deform into rigid sickle shapes that block capillaries and other small blood vessels. This blockage can lead to a wide range of serious, sometimes life-threatening, conditions including: chronic hemolytic anemia, chronic pain and acute painful crisis, stroke, acute chest syndrome, and cumulative damage to tissues and organs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $3.5M
- Funding stage: M&A
- Last round: Debt Financing (Dec 2013)
- Website: aesrx.com
- Phone: +1 6176636178
Industries & Categories
Biopharma, Biotechnology, Health Care
Canonical: https://fsome.com/organization/aesrx-2511073 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.